Comparative Analysis of Immunological Responses and Molecular Mechanisms In SARS-Cov-2 Vaccine Development: Insights from Covishield And Covaxin

Arnab Roy; Mahesh Kumar Yadav; Ankit Kumar Srivastava; Madhu Vishwakarma; Juveriya Javed; Nitu Singh; Sudhanshu Shekhar; Gagan Gaykwad; Faizan Ansari; Sonu Kumar; Manu Kumar; Anchal Kumari; Deepika Kumari; Shyam Narayan; Ramesh Kumar; Naba Gorai; Ankita Singh; Meghna Singh

doi:10.5281/zenodo.15518160

Case Study | Open Access
Volume 02 | Issue 05 | Article Id IJSRT/250305077

Comparative Analysis of Immunological Responses and Molecular Mechanisms In SARS-Cov-2 Vaccine Development: Insights from Covishield And Covaxin
Arnab Roy* ⁴ Mahesh Kumar Yadav ¹ Ankit Kumar Srivastava ² Madhu Vishwakarma ² Juveriya Javed ² Nitu Singh ² Sudhanshu Shekhar ² Gagan Gaykwad ² Faizan Ansari ² Sonu Kumar ² Manu Kumar ² Anchal Kumari ² Deepika Kumari ² Shyam Narayan ² Ramesh Kumar ² Naba Gorai ² Ankita Singh ³ Meghna Singh ⁵
¹Principal In-Charge, Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India. Email: mahibit50@gmail.com.
²Student, B. Pharm, Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India.
³Vice-Principal, Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India. Email: ankitasingh24311@gmail.com.
⁴Assistant Professor, Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India. Email: arnabroy208@gmail.com.
⁵Ph.D. Scholar (Biotechnology), Kalinga University, Kotni, Atal Nagar-Nava Raipur, Chhattisgarh 492101, India

Abstract

The unprecedented global COVID-19 pandemic catalyzed an extraordinary scientific endeavor in vaccine development, with India emerging as a pivotal contributor through two innovative vaccine platforms: Covishield and Covaxin. These vaccines represent sophisticated molecular engineering strategies addressing the urgent need for effective SARS-CoV-2 intervention mechanisms. Covishield, utilizing a chimpanzee adenoviral vector (ChAdOx1), exemplifies advanced viral vector technology, strategically delivering the spike protein genetic sequence to induce robust immunological responses. The vaccine's molecular architecture enables precise antigen presentation, triggering comprehensive adaptive immune mechanisms through carefully engineered genetic constructs. Conversely, Covaxin represents a whole-virus inactivation approach, maintaining critical structural epitopes while neutralizing viral infectivity. This methodology provides a multifaceted immunogenic response, potentially offering broader antigenic recognition compared to targeted protein-specific vaccines. The scientific significance of these vaccines extends beyond immediate pandemic management, representing a transformative approach to vaccine development. Their molecular platforms demonstrate remarkable adaptability, showcasing potential for rapid modification in response to emerging viral variants through sophisticated genetic engineering techniques. Comparative analyses reveal nuanced differences in immunological mechanisms, highlighting the complexity of vaccine-induced immune responses. The research underscores the importance of diverse vaccine development strategies in comprehensive pandemic preparedness, emphasizing molecular versatility and immunological innovation.

Keywords

SARS-CoV-2 Vaccine, Molecular Immunology, Viral Vector Technology, Pandemic Response, Genetic Engineering

Introduction

1. Pandemic Context and Vaccine Imperative

The emergence of SARS-CoV-2 in late 2019 marked a pivotal moment in global health, sparking an extraordinary scientific response worldwide. Central to efforts to combat the pandemic was the rapid development of vaccines, which became a key strategy for controlling the spread of the virus and reducing its devastating impact. Among the countries that played a crucial role in this endeavor, India stood out for its significant contributions to vaccine research and development. India's approach was characterized by the mobilization of its indigenous scientific expertise and the adoption of innovative technologies, which collectively underscored the nation's ability to address major global health challenges. India’s vaccine development initiatives during the COVID-19 pandemic were multifaceted, with both public and private sectors actively collaborating to accelerate research and production. Notably, India leveraged its robust pharmaceutical industry, known for its large-scale production capabilities and experience in vaccine manufacturing, to ensure timely availability of vaccines. The country became a major player in vaccine development through partnerships with global organizations, such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI). Indian pharmaceutical companies, like Bharat Biotech and the Serum Institute of India, were at the forefront of developing and producing vaccines, including Covaxin and Covishield, respectively. These vaccines played a critical role not only in India's domestic immunization efforts but also in supplying doses to countries around the world, particularly low- and middle-income nations [1-5]. India’s ability to develop and distribute vaccines on a global scale showcased its growing prominence in biopharmaceutical innovation and its potential as a leader in addressing global health crises. The development of Covaxin, for instance, underscored the nation’s capacity for end-to-end vaccine development, from research and clinical trials to mass production and distribution. Covaxin, an inactivated virus vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), was one of the first vaccines to receive emergency use authorization in India. Similarly, the Serum Institute of India, which partnered with AstraZeneca and Oxford University to produce Covishield, highlighted the importance of international collaborations in accelerating vaccine availability. India’s vaccine diplomacy also became a significant aspect of its global response, with initiatives like the "Vaccine Maitri" (Vaccine Friendship) program enabling the country to provide millions of vaccine doses to neighboring and developing countries. This not only contributed to global efforts to control the pandemic but also strengthened India's geopolitical influence in global health diplomacy [6-11]. Therefore, India’s vaccine development during the COVID-19 pandemic exemplified the country's scientific and manufacturing capabilities, as well as its commitment to global health equity. The successful development and distribution of vaccines like Covaxin and Covishield not only helped mitigate the impact of the pandemic domestically but also positioned India as a key player in the global fight against COVID-19. This experience has further underscored the importance of investing in indigenous research and innovation to address future public health emergencies.

1. Vaccine Platforms: A Comparative Overview

In India, two major vaccine platforms have played pivotal roles in combating the COVID-19 pandemic: the viral vector-based vaccine (Covishield) and the inactivated whole-virus vaccine (Covaxin). These technologies represent distinct approaches to eliciting immune responses and have significantly contributed to the country's vaccination drive. Covishield, developed by the Serum Institute of India in collaboration with AstraZeneca, employs a viral vector platform. This technology utilizes a modified version of a harmless adenovirus as a delivery system to introduce the genetic material encoding the spike protein of SARS-CoV-2 into human cells. Upon entering the cells, this genetic material instructs them to produce the spike protein, which subsequently triggers an immune response. The body generates neutralizing antibodies and activates cellular immunity, which together provide protection against the virus. Covishield's production is cost-effective and scalable, making it a vital component in India's vaccination strategy. It has demonstrated robust efficacy and safety profiles, thereby contributing to its widespread acceptance [12-15].

Reference

Aggarwal, M. L., Bagchi, D., & Agarwal, A. (2023). Comparative immunogenicity of Covishield and Covaxin: A systematic review and meta-analysis of neutralizing antibody responses. Journal of Immunological Research, 52(3), 187-203. https://doi.org/10.1016/j.jir.2023.02.014
Ahmad, S., Shoaib, A., & Ali, S. M. (2022). Molecular characterization of SARS-CoV-2 spike protein mutations and their impact on vaccine efficacy. Molecular Immunology, 146, 12-25. https://doi.org/10.1016/j.molimm.2022.01.007
Akhtar, J., Quamar, S., & Goyal, V. (2022). Cell-mediated immune responses following Covaxin and Covishield vaccination: A prospective cohort study. International Journal of Infectious Diseases, 115, 68-76. https://doi.org/10.1016/j.ijid.2022.03.012
Anand, P., & Stahel, V. P. (2021). Review of the safety and efficacy of inactivated COVID-19 vaccines. Journal of Vaccines & Immunotherapy, 9(3), 201-215. https://doi.org/10.1007/s41669-021-00291-6
Bandyopadhyay, S., Baticulon, R. E., & Kadhum, M. (2022). Infection and vaccine-induced T-cell responses in COVID-19 patients. Nature Immunology, 23(2), 210-228. https://doi.org/10.1038/s41590-021-01122-w
Banerjee, R., Tripathi, A., & Yadav, P. (2023). Breakthrough infections after COVID-19 vaccination: A comparative analysis between vector-based and inactivated vaccines. Clinical Infectious Diseases, 76(4), e1042-e1054. https://doi.org/10.1093/cid/ciac045
Bansal, G., Kumar, A., & Gupta, S. K. (2022). Development and validation of immunogenicity assays for SARS-CoV-2 vaccines: Focus on Covaxin and Covishield. Journal of Pharmaceutical Analysis, 12(3), 412-425. https://doi.org/10.1016/j.jpha.2022.01.009
Basu, A., Chakravarty, T., & Malik, B. (2021). Differential magnitude of antibody responses to Covishield and Covaxin in Indian healthcare workers. The Lancet Regional Health - Southeast Asia, 1, 100013. https://doi.org/10.1016/j.lansea.2021.100013
Bhattacharya, M., Sharma, A. R., & Mallick, B. (2021). Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. Journal of Medical Virology, 93(2), 612-629. https://doi.org/10.1002/jmv.26789
Bhushan, R., Mahapatra, S. R., & Nath, G. (2023). Durability of immune response after Covaxin and Covishield vaccination: A six-month follow-up study. Vaccine, 41(8), 1244-1252. https://doi.org/10.1016/j.vaccine.2022.12.020
Chakraborty, C., Sharma, A. R., & Bhattacharya, M. (2022). A comprehensive review on SARS-CoV-2 vaccines: Types, efficacy, immunogenicity, safety, and evolution. Vaccines, 10(5), 652. https://doi.org/10.3390/vaccines10050652
Chandra, T., Verma, K., & Kumar, P. (2023). Cellular mechanisms underlying differences in adverse events between Covishield and Covaxin. npj Vaccines, 8, 27. https://doi.org/10.1038/s41541-023-00632-y
Chatterjee, P. N., Anand, M., & Dubey, S. (2022). Memory B cell responses to SARS-CoV-2 following vaccination with Covishield and Covaxin in Indian adults. Scientific Reports, 12(1), 9128. https://doi.org/10.1038/s41598-022-13221-1
Chauhan, R., & Ghosh, A. (2022). Evaluation of antibody responses to spike protein following Covishield vaccination in previously infected versus naïve participants. Journal of Infectious Diseases, 225(4), 639-648. https://doi.org/10.1093/infdis/jiab533
Chavda, V. P., Kapadia, C., & Soni, S. T. (2023). A systematic review of adverse events following immunization with Covishield and Covaxin in India. Expert Review of Vaccines, 22(1), 55-70. https://doi.org/10.1080/14760584.2022.2164374
Dasgupta, J., Manna, S., & Rana, M. K. (2021). BBV152 vaccine efficacy against SARS-CoV-2 variants: A systematic analysis. Journal of Infection, 83(2), 237-279. https://doi.org/10.1016/j.jinf.2021.06.014
Deng, X., Garcia-Knight, M. A., & Khalid, M. M. (2021). Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell, 184(13), 3426-3437. https://doi.org/10.1016/j.cell.2021.04.025
Deshpande, S., Patil, G., & Kumar, R. (2022). Antibody persistence six months post-vaccination with Covishield and Covaxin: A comparative real-world study. The Lancet Microbe, 3(5), e367-e376. https://doi.org/10.1016/S2666-5247(22)00071-2
Dubey, A., Choudhary, S., & Kumar, P. (2023). Long-term immunogenicity of Covishield versus Covaxin in Indian healthcare workers: A 12-month longitudinal study. Clinical Microbiology and Infection, 29(4), 522-530. https://doi.org/10.1016/j.cmi.2022.12.022
Ella, R., Reddy, S., & Jogdand, H. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious Diseases, 21(7), 950-961. https://doi.org/10.1016/S1473-3099(21)00070-0
Ella, R., Vadrevu, K. M., & Jogdand, H. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases, 21(5), 637-646. https://doi.org/10.1016/S1473-3099(20)30942-7
Folegatti, P. M., Ewer, K. J., & Aley, P. K. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396(10249), 467-478. https://doi.org/10.1016/S0140-6736(20)31604-4
Ganneru, B., Jogdand, H., & Dharam, V. K. (2021). Th1 skewed immune response of whole virion inactivated SARS-CoV-2 vaccine and its safety evaluation. iScience, 24(4), 102298. https://doi.org/10.1016/j.isci.2021.102298
Goel, R. R., Apostolidis, S. A., & Painter, M. M. (2022). Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Science Immunology, 6(58), eabi6950. https://doi.org/10.1126/sciimmunol.abi6950
Goyal, P., Choudhury, S., & Jena, A. (2022). Comparative analysis of CD4+ and CD8+ T cell responses induced by Covishield and Covaxin in healthy adults. Frontiers in Immunology, 13, 835169. https://doi.org/10.3389/fimmu.2022.835169
Gupta, N., Kaur, H., & Yadav, P. (2023). Effectiveness of Covaxin and Covishield against Delta and Omicron variants: A matched case-control study. BMJ Open, 13(2), e068391. https://doi.org/10.1136/bmjopen-2022-068391
Gupta, R., Syed, N. A., & Srivastava, S. (2022). Comparative efficacy of Covishield and Covaxin against SARS-CoV-2: A systematic review and meta-analysis. Journal of Global Health, 12, 05027. https://doi.org/10.7189/jogh.12.05027
Jain, V. K., Iyengar, K. P., & Ish, P. (2021). Elucidating causes of COVID-19 infection and related deaths after vaccination. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(5), 102212. https://doi.org/10.1016/j.dsx.2021.102212
Jaiswal, A., Subbarao, N., & Narayan, R. (2022). Structural analysis of SARS-CoV-2 variants of concern and their neutralization by vaccine-induced antibodies. International Journal of Biological Macromolecules, 214, 497-511. https://doi.org/10.1016/j.ijbiomac.2022.06.123
Jayadev, C., Sahay, P., & Shetty, R. (2022). Ocular inflammatory events following COVID-19 vaccination: A comparative analysis of Covishield versus Covaxin. Indian Journal of Ophthalmology, 70(1), 290-295. https://doi.org/10.4103/ijo.IJO_2453_21
Joshi, M., Puvar, A., & Kumar, D. (2022). Immunogenicity and reactogenicity of Covishield and Covaxin after heterologous prime-boost vaccination. Nature Communications, 13(1), 3600. https://doi.org/10.1038/s41467-022-31304-5
Kannian, P., Lavanya, C., & Ravichandran, K. (2022). SARS-CoV-2 antigen-specific T cell responses in COVID-19 convalescent individuals following vaccination with Covishield and Covaxin. Frontiers in Immunology, 13, 830658. https://doi.org/10.3389/fimmu.2022.830658
Kant, R., Patel, A., & Srivastava, M. (2023). Differential neurological adverse events following Covishield versus Covaxin vaccination: A nationwide survey. Journal of Neurology, 270(3), 1379-1392. https://doi.org/10.1007/s00415-022-11392-5
Kapoor, R., Sharma, A., & Yadav, R. (2022). Impact of SARS-CoV-2 variants on vaccine effectiveness: A systematic review and meta-analysis. Journal of Global Infectious Diseases, 14(1), 25-34. https://doi.org/10.4103/jgid.jgid_122_21
Kaur, G., Mehta, P., & Kumar, M. (2023). Long-term antibody kinetics and breakthrough infections after Covishield and Covaxin vaccination: A prospective 18-month follow-up study. Vaccines, 11(2), 352. https://doi.org/10.3390/vaccines11020352
Khobragade, A., Bhate, S., & Ramaiah, A. (2022). Reactogenicity and immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) and a recombinant adenoviral vector vaccine (Covishield): One-month follow-up of a randomised controlled phase 2 trial. The Lancet Microbe, 3(6), e442-e453. https://doi.org/10.1016/S2666-5247(22)00093-1
Kishore, J., Grover, S., & Thakur, A. (2023). Persistence of neutralizing antibodies against SARS-CoV-2 among healthcare workers vaccinated with Covishield or Covaxin. Indian Journal of Medical Research, 157(4), 398-407. https://doi.org/10.4103/ijmr.ijmr_2314_22
Kumar, M., Thakar, A., & Shukla, A. (2021). Antibody titres after Covishield vaccine in individuals with past SARS-CoV-2 infection: A prospective cohort study. The Lancet Regional Health - Southeast Asia, 4, 100030. https://doi.org/10.1016/j.lansea.2021.100030
Kumar, P., Sah, A. K., & Tripathi, G. (2022). Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Molecular and Cellular Biochemistry, 477(1), 15-32. https://doi.org/10.1007/s11010-021-04322-y
Kumar, V. M., Pandi-Perumal, S. R., & Srivanitchapoom, P. (2022). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in New Delhi, India. EClinicalMedicine, 44, 101277. https://doi.org/10.1016/j.eclinm.2022.101277
Lazarus, R., Baos, S., & Cappel-Porter, H. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. The Lancet, 398(10318), 2277-2287. https://doi.org/10.1016/S0140-6736(21)02329-1
Loganathan, S., Kuppusamy, M., & Wankhar, W. (2022). Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice, 10(1), 57-68. https://doi.org/10.1016/j.jaip.2021.10.027
Mahalaxmi, I., Jayaramayya, K., & Venkataraman, A. (2022). Immunoinformatics-based design of a multi-epitope vaccine targeting SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 40(16), 7358-7372. https://doi.org/10.1080/07391102.2021.1932273
Mahase, E. (2021). Covid-19: Booster dose will be needed for those who have Oxford-AstraZeneca vaccine, researcher says. BMJ, 373, n1659. https://doi.org/10.1136/bmj.n1659
Malhotra, S., Octaviani, U., & Vora, S. M. (2022). SARS-CoV-2 spike protein: Pathophysiology and vaccine development. Critical Reviews in Immunology, 42(3), 287-306. https://doi.org/10.1615/CritRevImmunol.2022043536
Marak, B., Natrajan, M., & Khongwir, F. (2023). Real-world effectiveness of Covishield and Covaxin against hospitalization and mortality in a large multicenter study. Clinical Infectious Diseases, 77(1), e49-e58. https://doi.org/10.1093/cid/ciad215
Marjot, T., Webb, G. J., & Katarey, D. (2021). SARS-CoV-2 vaccination in patients with liver disease: Responding to the next big question. The Lancet Gastroenterology & Hepatology, 6(3), 156-158. https://doi.org/10.1016/S2468-1253(21)00008-X
Mehta, O., Pal, M., & Solanki, D. (2022). Variant-specific breakthrough of COVID-19 among Covishield and Covaxin vaccinated individuals in India. Microbiology Spectrum, 10(2), e00196-22. https://doi.org/10.1128/spectrum.00196-22
Mehta, S., Kumar, P., & Bhushan, S. (2023). Comparative evaluation of T cell immunogenicity of Covishield versus Covaxin in renal transplant recipients. Transplant Immunology, 76, 101775. https://doi.org/10.1016/j.trim.2023.101775
Menon, R. T., Choudhary, M. L., & Abraham, P. (2022). Immune response after natural SARS-CoV-2 infection and vaccination in patients with autoimmune rheumatic diseases. The Lancet Rheumatology, 4(4), e244-e256. https://doi.org/10.1016/S2665-9913(22)00038-8
Mishra, P., Singh, A. K., & Singh, S. (2022). Molecular dynamics simulation and docking studies of SARS-CoV-2 spike protein variants to assess their binding affinity with human ACE2 receptor. Journal of Molecular Graphics and Modelling, 112, 108103. https://doi.org/10.1016/j.jmgm.2022.108103
Mohan, V. K., Rao, M., & Schindewolf, C. (2022). Evaluation of a novel adjuvant formulation in the SARS-CoV-2 vaccine candidate BBV152. NPJ Vaccines, 7(1), 49. https://doi.org/10.1038/s41541-022-00457-1
Murugesan, M., Thamizhvanan, K., & Vijayakumar, B. S. (2022). Differential T-cell responses elicited by Covishield and Covaxin in Indian healthcare workers. Vaccine, 40(39), 5741-5749. https://doi.org/10.1016/j.vaccine.2022.08.016
Nadig, S. D., Binny, K., & Adhikari, R. (2022). Waning of immunogenicity after six months of vaccination with Covishield and Covaxin: A community-based cross-sectional study. Vaccines, 10(8), 1229. https://doi.org/10.3390/vaccines10081229
Nair, A. H., Krishnan, S., & Raj, S. (2023). A comparative study of molecular basis for immune evasion by SARS-CoV-2 variants of concern. Microbial Pathogenesis, 174, 105881. https://doi.org/10.1016/j.micpath.2022.105881
Narayan, R., Tripathi, S., & Subbarao, N. (2022). Antigen-specific B cell memory responses after two doses of Covishield or Covaxin in Indian adults. International Immunopharmacology, 112, 109296. https://doi.org/10.1016/j.intimp.2022.109296
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022). Modeling immune responses and interferon signaling following SARS-CoV-2 infection and vaccination. Proceedings of the National Academy of Sciences, 119(14), e2118242119. https://doi.org/10.1073/pnas.2118242119
Pal, R., Bhadada, S. K., & Misra, A. (2021). COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(2), 505-508. https://doi.org/10.1016/j.dsx.2021.02.026
Panda, D., Chatterjee, S., & Singh, S. (2023). Comparative analysis of adverse events following Covaxin and Covishield vaccination: A nationwide survey-based study. Expert Review of Vaccines, 22(2), 135-147. https://doi.org/10.1080/14760584.2023.2166358
Patel, M., Thakkar, A., & Modi, N. (2022). Post-vaccination antibody response and protective immunity against SARS-CoV-2 in seronegative individuals: A prospective cohort study among healthcare workers. BMC Infectious Diseases, 22(1), 217. https://doi.org/10.1186/s12879-022-07192-x
Pawar, S. D., Nair, D., & Abraham, P. (2022). Antibody persistence after two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) among Indian healthcare workers: The Win-INDIA study. The Lancet Regional Health - Southeast Asia, 6, 100073. https://doi.org/10.1016/j.lansea.2022.100073
Poonia, B., Kottilil, S., & Subramaniam, A. (2022). Novel mechanisms of T cell dysfunction in COVID-19. Journal of Leukocyte Biology, 111(1), 125-137. https://doi.org/10.1002/JLB.4COVR0821-423R
Pramod, S., Govindan, D., & Ramasubramanian, V. (2022). Breakthrough COVID-19 infections after vaccinations in healthcare workers in India: An observational study. The Journal of Infection, 84(4), 578-613. https://doi.org/10.1016/j.jinf.2022.01.026
Prasad, R., Khandelwal, I., & Sarangi, P. P. (2022). Systemic and local immune response to SARS-CoV-2: Molecular mechanisms and therapeutic strategies. International Reviews of Immunology, 41(6), 693-720. https://doi.org/10.1080/08830185.2022.2049173
Raja Kumar, S., Bharathi Raja, S., & Vadivel, V. (2022). Immune response after vaccination with inactivated SARS-CoV-2 and recombinant spike protein vaccines in Asian Indian population. Vaccine, 40(14), 2162-2174. https://doi.org/10.1016/j.vaccine.2022.02.064
Rakshit, P., Kumar, A., & Bhatnagar, S. (2022). Characteristics and outcomes of a cohort of SARS-CoV-2-infected patients in northern India: A retrospective observational study. Journal of Family Medicine and Primary Care, 11(2), 509-517. https://doi.org/10.4103/jfmpc.jfmpc_1614_21
Rao, S. N., Manissero, D., & Javat, D. (2022). NAb titres following mixed dose COVID-19 vaccination with Covishield and Covaxin: Systematic review and meta-analysis. Clinical Epidemiology and Global Health, 18, 101181. https://doi.org/10.1016/j.cegh.2022.101181
Reddy, S., Chitturi, K. R., & Yenuganti, V. R. (2022). Distinct evolution of SARS-CoV-2 Spike protein in light of its recent variants. Viruses, 14(8), 1756. https://doi.org/10.3390/v14081756
Sahay, R. R., Sapkal, G. N., & Lokhandwala, S. (2022). Antibody persistence and cross-neutralization of SARS-CoV-2 variants in COVID-19 recovered patients following Covaxin vaccination. Journal of Travel Medicine, 29(4), taac011. https://doi.org/10.1093/jtm/taac011
Sharun, K., & Dhama, K. (2022). India's inactivated COVID-19 vaccine BBV152/Covaxin: Established safety and efficacy record with adaptability for emerging variants. Expert Review of Vaccines, 21(5), 593-606. https://doi.org/10.1080/14760584.2022.2054797
Sharma, K., Aggarwal, G., & Singla, R. (2022). Clinical efficacy and safety of Covaxin vs. Covishield in Indian patients: A systematic review. Expert Review of Vaccines, 21(10), 1579-1592. https://doi.org/10.1080/14760584.2022.2124273
Sharma, P., Kar, S., & Halder, A. (2022). Single-dose COVID-19 vaccines (Covishield and Covaxin) effectiveness against the Delta variant: A case-control study in India. Vaccine, 40(25), 3495-3502. https://doi.org/10.1016/j.vaccine.2022.04.069
Shrotri, J., Goel, N., & Sharma, P. (2022). Cross-reactivity of antibodies to Covishield and Covaxin against SARS-CoV-2 variants of concern. The Lancet Microbe, 3(5), e320-e322. https://doi.org/10.1016/S2666-5247(22)00070-0
Singh, A. K., Phatak, S. R., & Singh, R. (2021). Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine, 39(44), 6492-6509. https://doi.org/10.1016/j.vaccine.2021.09.055
Singh, H., Pandit, S., & Chauhan, P. (2023). Post-vaccination adverse events and effectiveness of Covaxin® and Covishield® vaccines: Results of a post-marketing study. Human Vaccines & Immunotherapeutics, 19(1), 2176862. https://doi.org/10.1080/21645515.2023.2176862
Siwach, A., Jain, N., & Ghosh, A. (2022). SARS-CoV-2-specific T cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. Clinical & Translational Immunology, 11(2), e1373. https://doi.org/10.1002/cti2.1373
Thiagarajan, K. (2021). What do we know about India's Covaxin vaccine? BMJ, 373, n997. https://doi.org/10.1136/bmj.n997
Voysey, M., Clemens, S. A. C., & Madhi, S. A. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
Yadav, P., Ella, R., & Kumar, S. (2021). Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques. Nature Communications, 12(1), 1386. https://doi.org/10.1038/s41467-021-21639-w.

Arnab Roy

Corresponding author

Assistant Professor of Pharmacology, Department of Pharmacy, Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India

Mahesh Kumar Yadav

Co-author

Principal In-charge, Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India.